Autolus Therapeutics (AUTL) Q4 2022 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2022 earnings summary
9 Nov, 2026Executive summary
Clinical-stage programmed T-cell therapy developer with no approved products or product sales; 2022 revenue came from intellectual-property licensing. Net loss widened to £117.4m from £102.3m.
Cash and cash equivalents were £316.3m at year-end; management assessed funding to last through 30 June 2024, including under modeled downside scenarios.
Financial highlights
License revenue rose to £5.3m from £1.1m, reflecting Moderna’s option exercise and the BMS license upfront payment.
R&D expense increased 17% to £112.6m from £96.1m; G&A rose to £28.2m from £23.5m.
Operating loss was £136.8m versus £116.1m; income tax benefit was £19.3m versus £16.2m.
Net loss was £117.4m versus £102.3m; basic and diluted loss per share was £1.24 versus £1.42.
Outlook and guidance
Significant expenses are expected to continue as candidates advance through development, regulatory review and potential commercialization; substantial additional funding will be needed.
Cash forecasts, including sensitivities for clinical delays, inflation and lower R&D tax credits, showed sufficient liquidity through 30 June 2024; headcount reductions and cost delays were identified as levers.
Profitability depends on successful development, approval and commercialization of candidates and revenue sufficient to support the cost base.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026